Preclinical evaluation of a hypotonic docetaxel nanosuspension formulation for intravesical treatment of non-muscle-invasive bladder cancer.
Chemotherapy
N-methyl-N-nitrosourea (MNU)
Nanomilling
Pluronic
Taxotere
Urothelium
Journal
Drug delivery and translational research
ISSN: 2190-3948
Titre abrégé: Drug Deliv Transl Res
Pays: United States
ID NLM: 101540061
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
accepted:
13
10
2020
pubmed:
10
11
2020
medline:
8
4
2022
entrez:
9
11
2020
Statut:
ppublish
Résumé
Intravesical chemotherapy is a key approach for treating refractory non-muscle-invasive bladder cancer (NMIBC). However, the effectiveness of intravesical chemotherapy is limited by bladder tissue penetration and retention. Here, we describe the development of a docetaxel nanosuspension that, when paired with a low osmolality (hypotonic) vehicle, demonstrates increased uptake by the bladder urothelium with minimal systemic exposure. We compare the bladder residence time and efficacy in an immune-competent rat model of NMIBC to the clinical comparator, solubilized docetaxel (generic Taxotere) diluted for intravesical administration. We found that only the intravesical docetaxel nanosuspension significantly decreased cell proliferation compared to untreated tumor tissues. The results presented here suggest that the combination of nanoparticle-based chemotherapy and a hypotonic vehicle can provide more efficacious local drug delivery to bladder tissue for improved treatment of refractory NMIBC.
Identifiants
pubmed: 33164163
doi: 10.1007/s13346-020-00870-w
pii: 10.1007/s13346-020-00870-w
doi:
Substances chimiques
Docetaxel
15H5577CQD
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2085-2095Subventions
Organisme : NCRR NIH HHS
ID : S10 RR026824
Pays : United States
Informations de copyright
© 2020. Controlled Release Society.
Références
Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133–45.
doi: 10.1002/ijc.27711
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2015;65(1):5–29.
doi: 10.3322/caac.21254
Kamat AM, Sylvester RJ, Bohle A, Palou J, Lamm DL, Brausi M, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J Clin Oncol. 2016;34(16):1935–44.
doi: 10.1200/JCO.2015.64.4070
Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124–9.
doi: 10.1016/S0022-5347(05)67707-5
Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93(4):485–90.
doi: 10.1111/j.1464-410X.2003.04655.x
Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guerin therapy. J Urol. 2013;189(3):834–9.
doi: 10.1016/j.juro.2012.10.068
Riou JF, Naudin A, Lavelle F. Effects of Taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun. 1992;187(1):164–70.
doi: 10.1016/S0006-291X(05)81474-3
Song D, Wientjes MG, Au JL. Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol. 1997;40(4):285–92.
doi: 10.1007/s002800050660
Cornish J, Nickel JC, Vanderwee M, Costerton JW. Ultrastructural visualization of human bladder mucous. Urol Res. 1990;18(4):263–6.
doi: 10.1007/BF00294770
Cornish J, Vanderwee M, Miller T. Mucus stabilization in the urinary bladder. Br J Exp Pathol. 1987;68(3):369–75.
pubmed: 3620331
pmcid: 2013262
Grist M, Chakraborty J. Identification of a mucin layer in the urinary bladder. Urology. 1994;44(1):26–33.
doi: 10.1016/S0090-4295(94)80005-7
Parsons CL. The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis. Urology. 2007;69:9–16.
doi: 10.1016/j.urology.2006.03.084
Stojnev S, Ristic-Petrovic A, Velickovic LJ, Krstic M, Bogdanovic D, Khanh do T, et al. Prognostic significance of mucin expression in urothelial bladder cancer. Int J Clin Exp Pathol. 2014;7(8):4945–58.
pubmed: 25197366
pmcid: 4152056
Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev. 2012;64(6):557–70.
doi: 10.1016/j.addr.2011.12.009
Lai SK, O’Hanlon DE, Harrold S, Man ST, Wang YY, Cone R, et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A. 2007;104(5):1482–7.
doi: 10.1073/pnas.0608611104
Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61(2):158–71.
doi: 10.1016/j.addr.2008.11.002
Ensign LM, Tang BC, Wang YY, Tse TA, Hoen T, Cone R, et al. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med. 2012;4(138):138ra79.
Maisel K, Ensign L, Reddy M, Cone R, Hanes J. Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse. J Control Release. 2015;197:48–57.
doi: 10.1016/j.jconrel.2014.10.026
Mastorakos P, da Silva AL, Chisholm J, Song E, Choi WK, Boyle MP, et al. Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy. Proc Natl Acad Sci U S A. 2015;112(28):8720–5.
doi: 10.1073/pnas.1502281112
Ensign LM, Hoen TE, Maisel K, Cone RA, Hanes JS. Enhanced vaginal drug delivery through the use of hypotonic formulations that induce fluid uptake. Biomaterials. 2013;34(28):6922–9.
doi: 10.1016/j.biomaterials.2013.05.039
Maisel K, Chattopadhyay S, Moench T, Hendrix C, Cone R, Ensign LM, et al. Enema ion compositions for enhancing colorectal drug delivery. J Control Release. 2015;209:280–7.
doi: 10.1016/j.jconrel.2015.04.040
Date AA, Halpert G, Babu T, Ortiz J, Kanvinde P, Dimitrion P, et al. Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease. Biomaterials. 2018;185:97–105.
doi: 10.1016/j.biomaterials.2018.09.005
Hoang T, Zierden H, Date A, Ortiz J, Gumber S, Anders N, et al. Development of a mucoinert progesterone nanosuspension for safer and more effective prevention of preterm birth. J Control Release. 2019;295:74–86.
doi: 10.1016/j.jconrel.2018.12.046
Yu T, Chisholm J, Choi WJ, Anonuevo A, Pulicare S, Zhong W, et al. Mucus-penetrating nanosuspensions for enhanced delivery of poorly soluble drugs to mucosal surfaces. Adv Healthc Mater. 2016;5(21):2745–50.
doi: 10.1002/adhm.201600599
Nance EA, Woodworth GF, Sailor KA, Shih TY, Xu Q, Swaminathan G, et al. A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci Transl Med. 2012;4(149):149ra19.
doi: 10.1126/scitranslmed.3003594
Steinberg GD, Brendler CB, Ichikawa T, Squire RA, Isaacs JT. Characterization of an N-methyl-N-nitrosourea-induced autochthonous rat bladder cancer model. Cancer Res. 1990;50(20):6668–74.
pubmed: 2208131
Kates M, Nirschl T, Sopko NA, Matsui H, Kochel CM, Reis LO, et al. Intravesical BCG induces CD4(+) T-cell expansion in an immune competent model of bladder cancer. Cancer Immunol Res. 2017;5(7):594–603.
doi: 10.1158/2326-6066.CIR-16-0267
Kates M, Date A, Yoshida T, Afzal U, Kanvinde P, Babu T, et al. Preclinical evaluation of intravesical cisplatin nanoparticles for non-muscle-invasive bladder cancer. Clin Cancer Res. 2017;23(21):6592–601.
doi: 10.1158/1078-0432.CCR-17-1082
McKiernan JM, Masson P, Murphy AM, Goetzl M, Olsson CA, Petrylak DP, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol. 2006;24(19):3075–80.
doi: 10.1200/JCO.2005.03.1161
Bridges JW, Sargent NS, Upshall DG. Rapid absorption from the urinary bladder of a series of n-alkyl carbamates: a route for the recirculation of drugs. Br J Pharmacol. 1979;66(2):283–9.
doi: 10.1111/j.1476-5381.1979.tb13677.x
Engelmann U, Oelsner G, Burger RA, Wagner H. Permeability of the rat bladder to Cisplatinum under different conditions: comparison with Mitomycin C and Adriamycin. Urol Res. 1983;11(1):39–42.
doi: 10.1007/BF00272708
Lavelle JP, Apodaca G, Meyers SA, Ruiz WG, Zeidel ML. Disruption of guinea pig urinary bladder permeability barrier in noninfectious cystitis. Am J Physiol. 1998;274(1 Pt 2):F205–14.
pubmed: 9458841
Negrete HO, Lavelle JP, Berg J, Lewis SA, Zeidel ML. Permeability properties of the intact mammalian bladder epithelium. Am J Physiol. 1996;271(4 Pt 2):F886–94.
pubmed: 8898019
Lewis SA, de Moura JL. Apical membrane area of rabbit urinary bladder increases by fusion of intracellular vesicles: an electrophysiological study. J Membr Biol. 1984;82(2):123–36.
doi: 10.1007/BF01868937
Chang A, Hammond TG, Sun TT, Zeidel ML. Permeability properties of the mammalian bladder apical membrane. Am J Physiol. 1994;267(5 Pt 1):C1483–92.
doi: 10.1152/ajpcell.1994.267.5.C1483
Grundy PL, Budd DW, England R. A randomized controlled trial evaluating the use of sterile water as an irrigation fluid during transurethral electrovaporization of the prostate. Br J Urol. 1997;80(6):894–7.
doi: 10.1046/j.1464-410X.1997.00458.x
Truzzi JC, Bruschini H, Srougi M, Ortiz V. Assessment of urodynamic bladder behavior on filling with solutions representing physiological extremes of urinary osmolarity. Int Braz J Urol. 2005;31(6):569–78.
doi: 10.1590/S1677-55382005000600011
Mugabe C, Matsui Y, So AI, Gleave ME, Baker JH, et al. In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer. Clin Cancer Res. 2011;17(9):2788-98.
doi: 10.1158/1078-0432.CCR-10-2981
Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, et al. Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol. 2020;203(5):902-9.
doi: 10.1097/JU.0000000000000688